2025 GU ASCO Bladder Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from GU ASCO 2025. Highlights in this video include: • CheckMate274: Adjuvant Nivolumab for high risk resected bladder cancer maintains DFS benefit with trend towards OS • NIAGARA: Perioperative Durvalumab with chemotherapy for muscle invasive bladder cancer associated with higher CR • INDUCT: Neoadjuvant Durvalumab with chemotherapy shows promise in upper tract urothelial carcinoma
▶︎
Muscle Invasive Bladder Cancer
▶︎
Perioperative Durvalumab FDA Approval New Standard for Muscle Invasive Bladder Cancer
▶︎
2025 GU ASCO Prostate Cancer Highlights
▶︎
Genitourinary Cancers: New Advances in 2025
▶︎
Advanced Pancreatic Cancer Treatments in 2026: What you need to know.
▶︎
2025 Updates in the Management of SMM/MGUS and the Prevention of Progression
▶︎
Baim Grand Rounds Manesh Patel 08Jun2026
▶︎
Bladder Cancer: NON-Muscle Invasive (Superficial Bladder Cancer)
▶︎
Updates in Prostate Cancer Treatment: ASCO GU 2025 Highlights
▶︎
RASolute 302 Pancreatic Cancer Study with Daraxonrasib at ASCO 2026 – Dr. Brian Wolpin
▶︎
How Proctor’s texts in Karen Read lawsuit could free dangerous criminals
▶︎
I Spent 20 Days Building the Cheapest Forest House Alone to Live: Solo Bushcraft (Full)
▶︎
Bladder Cancer Breakthroughs 2025: New Treatments & Bladder-Sparing Advances
▶︎
Updates in Multiple Myeloma in 2025: From Bench to Bedside
▶︎
These Two Drugs Eliminated Cancer Metastasis | Here's What You Need to Know
▶︎
Bladder Cancer - Overview (types, pathophysiology, diagnosis, treatment)
▶︎
Advancing the treatment of muscle-invasive bladder cancer
▶︎
ASCO 2025 - GU Cancer Highlights: KEYNOTE-564, AMPLITUDE, ARANOTE, NIAGARA
▶︎
Bladder Cancer Explained: Risk Factors, Symptoms & Treatment
▶︎